![7-(2,2-DIMETHYL-5-OXO-4-PHENYL-IMIDAZOLIDIN-1-YL)-3,3-DIMETHYL-6-OXO-2-THIA-5-AZABICYCLO[3.2.0]HEPTANE-4-CARBOXYLIC ACID](https://img.chemicalbook.com/CAS/GIF/3511-16-8.gif)
LN-127413
7-(2,2-DIMETHYL-5-OXO-4-PHENYL-IMIDAZOLIDIN-1-YL)-3,3-DIMETHYL-6-OXO-2-THIA-5-AZABICYCLO[3.2.0]HEPTANE-4-CARBOXYLIC ACID , 99.9% , 3511-16-8
Update time: 2023-04-23
PRODUCT Properties
| Melting point: | 189.2-191.0° |
| alpha | D25 +366° (pyridine) |
| Boiling point: | 648.4±55.0 °C(Predicted) |
| Density | 1.43±0.1 g/cm3(Predicted) |
| storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly), Pyridine (Slightly) |
| form | Solid |
| pka | 2.45±0.50(Predicted) |
| color | White to Off-White |
| Stability: | Hygroscopic, Unstable in Solution |
Description and Uses
Hetacillin was synthesized by Bristol-Myers Laboratories in 1964. It shows activity as strong as that of ampicillin against a variety of gram-positive and gram-negative bacteria. Hetacillin shows almost the same pharmacokinetic properties as ampicillin when administered orally and a later serum peak when given by intramuscular administration. When administered either orally or intramuscularly, it is hydrolyzed in vivo into ampicillin. Therefore, the clinical applications of hetacillin are the same as those of ampicillin.
Antibacterial.
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Danger |
| Hazard statements | H334-H317 |
| Precautionary statements | P261-P285-P304+P341-P342+P311-P501-P261-P272-P280-P302+P352-P333+P313-P321-P363-P501 |
